Amgen, Inc. is exploring the combination of a lower dose of its KRAS G12C inhibitor Lumakras (sotorasib) with Merck & Co., Inc.’s Keytruda (pembrolizumab) in first-line non-small cell lung cancer after data from a Phase I safety study showed high levels of liver toxicity for the two-drug combination. The question is whether the combination will ultimately show an acceptable safety-efficacy profile, or whether it might open the door for competitor Mirati Therapeutics, Inc.’s KRAS G12C inhibitor adagrasib.
The company announced the data from the Phase Ib CodeBreaK 100 and 101 studies, combining Lumakras with either Keytruda or...






